DPP

亜型選択性的な製品

DPP-2 DPP-4 DPP-8 DPP-9

シグナル伝達経路

DPP製品

All (19)
DPP阻害剤 (18)
DPP抗体(1)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S5079	Sitagliptin	Sitagliptin (MK-0431) is an oral and highly selective DPP-4 inhibitor with an IC50 of 18 nM. It is used for the treatment of type 2 diabetes.	OPARU, 2024, 10.18725/OPARU-52005 Mol Biotechnol, 2023, 10.1007/s12033-023-00992-9 bioRxiv, 2023, 10.1101/2023.12.18.572126
S3033	Vildagliptin	Vildagliptin inhibits DPP−4 with IC50 of 2.3 nM.	Int J Mol Sci, 2024, 25(18)9760 J Clin Invest, 2023, 133(12)e165933 Oncoimmunology, 2023, 12(1):2268257
S4002	Sitagliptin phosphate monohydrate	Sitagliptin phosphate monohydrate (MK-0431) is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.	Front Oncol, 2021, 11:704024 J Biomol Struct Dyn, 2021, 1-12 J Diabetes Res, 2020, 2020:2450781
S1540	Saxagliptin (BMS-477118)	Saxagliptin (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.	Turk J Pharm Sci, 2019, 16(2):227-233 Cancer Cell, 2018, 34(4):659-673 J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1083:249-257
S8455	Talabostat (PT-100)	Talabostat (Val-boroPro, PT-100) is a dipeptidyl peptidase inhibitor with IC50 values of <4 nM, 4 nM, 11 nM, 310 nM, 560 nM and 390 nM for DPP-IV, DPP8, DPP9, QPP, FAP and PEP respectively. It has antineoplastic and hematopoiesis- stimulating activities.	J Oral Microbiol, 2024, 16(1):2373040 Brain Res, 2024, S0006-8993(24)00383-4 Nat Chem Biol, 2023, 19(4):431-439
S9631	Puromycin aminonucleoside	Puromycin aminonucleoside (NSC 3056, PAN, Stylomycin aminonucleoside, ARDMA, SAN), the aminonucleoside portion of the antibiotic puromycin, is a reversible inhibitor of dipeptidyl-peptidase II and cytosol alanyl aminopeptidase that induces apoptosis in mesangial cells (MCs) accompanied by declined cell viability and enhanced inflammatory response.	Cell Mol Biol Lett, 2023, 28(1):62 Cell Mol Biol Lett, 2023, 28(1):62 Oral Dis, 2022, 10.1111/odi.14321
S8565	Omarigliptin (MK-3102)	Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5).	NYMC Student Theses and Dissertations, 2023, Acta Pharmacol Sin, 2021, 1-9 Front Behav Neurosci, 2021, 15:705579
S2868	Alogliptin (SYR-322) benzoate	Alogliptin (SYR-322) benzoate is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.	Cell Rep, 2017, 20(7):1692-1704
S5365	Alogliptin	Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4)with IC50 values of 2.63 nM and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9.	Sci Adv, 2021, 7(27)eabh3032
S4697	Saxagliptin hydrate	Saxagliptin H2O (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.	Turk J Pharm Sci, 2019, 16(2):227-233
E4814^New	Teneligliptin Hydrobromide Hydrate	Teneligliptin Hydrobromide Hydrate(MP-513 hydrobromide hydrate) is a potent, competitive, and long-lasting inhibitor of DPP-4. It competitively inhibited rhDPP-4, human plasma, and rat plasma with IC50 values of 0.889, 1.75, and 1.35 nM respectively. It suppresses high glucose-mediated mitochondrial dysfunction and can be used for treatment of type 2 diabetes.
E1188^New	Brensocatib	Brensocatib (AZD7986, INS1007) is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1). It reduces the activity of all major neutrophil serine proteases (NSPs) including, neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in patients with bronchiectasis.	Nat Commun, 2024, 15(1):6519
E4804^New	Sitagliptin phosphate	Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of dipeptidyl peptidase IV (DPP-4) with an IC50 value of 19 nM in Caco-2 cell extracts.
S5909	Anagliptin	Anagliptin is an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor and exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
E4916^New	Bestatin hydrochloride	Bestatin hydrochloride is an inhibitor of aminopeptidase N and enkephalinase that elevates the levels of angiotensin II and angiotensin III. It also acts as a non-competitive inhibitor (α > 1) of porcine DPP-IV with a Ki value of 75 μM. It reduces DPP-IV activity, decreases cell viability, and increases DNA fragmentation in vitro. It has the potential to treat skin conditions like acne, psoriasis and keloids.
A2517	Begelomab (Anti-DPP4 / CD26)	Begelomab (Anti-DPP4 / CD26) is a murine IgG2b monoclonal antibody targeting DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. MW: 145.5 KD.
S7513	Trelagliptin	Trelagliptin (SYR-472), a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM, improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
S5063	Trelagliptin succinate	Trelagliptin succinate (SYR472) is a dipeptidyl peptidase IV (DPP-4) inhibitor which is used as a new long-acting drug for once-weekly treatment of type 2 diabetes mellitus (DM).
E0122	Gemigliptin	Gemigliptin (Zemiglo, LC15-0444) is a potent, selective and long-acting dipeptidyl peptidase 4 (DPP 4) inhibitor with a Ki of 7.25 nM. Gemigliptin shows at least >23,000-fold selectivity for DPP-4 over various proteases and peptidases, including DPP-8, DPP-9, and fibroblast activation protein (FAP)-α.
S5079	Sitagliptin	Sitagliptin (MK-0431) is an oral and highly selective DPP-4 inhibitor with an IC50 of 18 nM. It is used for the treatment of type 2 diabetes.	OPARU, 2024, 10.18725/OPARU-52005 Mol Biotechnol, 2023, 10.1007/s12033-023-00992-9 bioRxiv, 2023, 10.1101/2023.12.18.572126
S3033	Vildagliptin	Vildagliptin inhibits DPP−4 with IC50 of 2.3 nM.	Int J Mol Sci, 2024, 25(18)9760 J Clin Invest, 2023, 133(12)e165933 Oncoimmunology, 2023, 12(1):2268257
S4002	Sitagliptin phosphate monohydrate	Sitagliptin phosphate monohydrate (MK-0431) is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.	Front Oncol, 2021, 11:704024 J Biomol Struct Dyn, 2021, 1-12 J Diabetes Res, 2020, 2020:2450781
S1540	Saxagliptin (BMS-477118)	Saxagliptin (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.	Turk J Pharm Sci, 2019, 16(2):227-233 Cancer Cell, 2018, 34(4):659-673 J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1083:249-257
S8455	Talabostat (PT-100)	Talabostat (Val-boroPro, PT-100) is a dipeptidyl peptidase inhibitor with IC50 values of <4 nM, 4 nM, 11 nM, 310 nM, 560 nM and 390 nM for DPP-IV, DPP8, DPP9, QPP, FAP and PEP respectively. It has antineoplastic and hematopoiesis- stimulating activities.	J Oral Microbiol, 2024, 16(1):2373040 Brain Res, 2024, S0006-8993(24)00383-4 Nat Chem Biol, 2023, 19(4):431-439
S9631	Puromycin aminonucleoside	Puromycin aminonucleoside (NSC 3056, PAN, Stylomycin aminonucleoside, ARDMA, SAN), the aminonucleoside portion of the antibiotic puromycin, is a reversible inhibitor of dipeptidyl-peptidase II and cytosol alanyl aminopeptidase that induces apoptosis in mesangial cells (MCs) accompanied by declined cell viability and enhanced inflammatory response.	Cell Mol Biol Lett, 2023, 28(1):62 Cell Mol Biol Lett, 2023, 28(1):62 Oral Dis, 2022, 10.1111/odi.14321
S8565	Omarigliptin (MK-3102)	Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5).	NYMC Student Theses and Dissertations, 2023, Acta Pharmacol Sin, 2021, 1-9 Front Behav Neurosci, 2021, 15:705579
S2868	Alogliptin (SYR-322) benzoate	Alogliptin (SYR-322) benzoate is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.	Cell Rep, 2017, 20(7):1692-1704
S5365	Alogliptin	Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4)with IC50 values of 2.63 nM and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9.	Sci Adv, 2021, 7(27)eabh3032
S4697	Saxagliptin hydrate	Saxagliptin H2O (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.	Turk J Pharm Sci, 2019, 16(2):227-233
E4814^New	Teneligliptin Hydrobromide Hydrate	Teneligliptin Hydrobromide Hydrate(MP-513 hydrobromide hydrate) is a potent, competitive, and long-lasting inhibitor of DPP-4. It competitively inhibited rhDPP-4, human plasma, and rat plasma with IC50 values of 0.889, 1.75, and 1.35 nM respectively. It suppresses high glucose-mediated mitochondrial dysfunction and can be used for treatment of type 2 diabetes.
E1188^New	Brensocatib	Brensocatib (AZD7986, INS1007) is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1). It reduces the activity of all major neutrophil serine proteases (NSPs) including, neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in patients with bronchiectasis.	Nat Commun, 2024, 15(1):6519
E4804^New	Sitagliptin phosphate	Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of dipeptidyl peptidase IV (DPP-4) with an IC50 value of 19 nM in Caco-2 cell extracts.
S5909	Anagliptin	Anagliptin is an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor and exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
E4916^New	Bestatin hydrochloride	Bestatin hydrochloride is an inhibitor of aminopeptidase N and enkephalinase that elevates the levels of angiotensin II and angiotensin III. It also acts as a non-competitive inhibitor (α > 1) of porcine DPP-IV with a Ki value of 75 μM. It reduces DPP-IV activity, decreases cell viability, and increases DNA fragmentation in vitro. It has the potential to treat skin conditions like acne, psoriasis and keloids.
S7513	Trelagliptin	Trelagliptin (SYR-472), a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM, improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
S5063	Trelagliptin succinate	Trelagliptin succinate (SYR472) is a dipeptidyl peptidase IV (DPP-4) inhibitor which is used as a new long-acting drug for once-weekly treatment of type 2 diabetes mellitus (DM).
E0122	Gemigliptin	Gemigliptin (Zemiglo, LC15-0444) is a potent, selective and long-acting dipeptidyl peptidase 4 (DPP 4) inhibitor with a Ki of 7.25 nM. Gemigliptin shows at least >23,000-fold selectivity for DPP-4 over various proteases and peptidases, including DPP-8, DPP-9, and fibroblast activation protein (FAP)-α.
A2517	Begelomab (Anti-DPP4 / CD26)	Begelomab (Anti-DPP4 / CD26) is a murine IgG2b monoclonal antibody targeting DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. MW: 145.5 KD.
E4814^New	Teneligliptin Hydrobromide Hydrate	Teneligliptin Hydrobromide Hydrate(MP-513 hydrobromide hydrate) is a potent, competitive, and long-lasting inhibitor of DPP-4. It competitively inhibited rhDPP-4, human plasma, and rat plasma with IC50 values of 0.889, 1.75, and 1.35 nM respectively. It suppresses high glucose-mediated mitochondrial dysfunction and can be used for treatment of type 2 diabetes.
E1188^New	Brensocatib	Brensocatib (AZD7986, INS1007) is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1). It reduces the activity of all major neutrophil serine proteases (NSPs) including, neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in patients with bronchiectasis.	Nat Commun, 2024, 15(1):6519
E4804^New	Sitagliptin phosphate	Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of dipeptidyl peptidase IV (DPP-4) with an IC50 value of 19 nM in Caco-2 cell extracts.
E4916^New	Bestatin hydrochloride	Bestatin hydrochloride is an inhibitor of aminopeptidase N and enkephalinase that elevates the levels of angiotensin II and angiotensin III. It also acts as a non-competitive inhibitor (α > 1) of porcine DPP-IV with a Ki value of 75 μM. It reduces DPP-IV activity, decreases cell viability, and increases DNA fragmentation in vitro. It has the potential to treat skin conditions like acne, psoriasis and keloids.

DPP阻害剤の選択性比較